Citalopram and viloxazine in the treatment of depression by means of slow drop infusion. A double-blind comparative trial

Journal of Affective Disorders

Volumn 46, Issue 1, 1997, Pages 51-58

  Bouchard, J M ^a   Strub, N ^b   Nil, R ^c   Bellazouz, D ^d   Fray, P ^d   Peze E ^a   Charbonnier, J F ^e   Delisle, J P ^d   Hamza, H ^d   Faruch, M ^d   Moles, M F ^d   Varet Legros, M G ^f   Gavarret, P ^f   Nasrallah, R ^g   Van Amerongen, P ^g   Verdeau Pailles J ^h   Zaykine, G ^h  

^a Centre Hospitalier Gerard Marchant   (France)

^b Lundbeck   (France)

^c H LUNDBECK A S   (Denmark)

^d CHRU Saint Jacques ^*

^e Hopital Saint Jacques Clermont Ferrand   (France)

^f CENTRE HOSPITALIER   (France)

^g CENTRE HOSPITALIER INTERCOMMUNAL   (France)

^h Polyclinique Neuro psychiatrique   (France)

Author keywords

Antidepressant; Citalopram; Infusion; Viloxazine

Indexed keywords

CITALOPRAM; VILOXAZINE;

ADULT; AGED; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEADACHE; HEART PALPITATION; HUMAN; HYPERSOMNIA; INSOMNIA; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TREMOR; VERTIGO;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PERSONALITY INVENTORY; TREATMENT OUTCOME; VILOXAZINE;

EID: 0030781186     PISSN: 01650327     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-0327(97)00078-5     Document Type: Article

References (24)

1. Baldwin, D.S., Johnson, F.N., 1995. Tolerability and safety of citalopram. Rev. Contemp. Pharmacother. 6, 315-325.
2. Bech, P., Ciadella, P., 1992. Citalopram in depression-meta-analysis of intended and unintended effects. Int. Clin. Psychopharmacol. 6 (Suppl. 5), 45-54.
3. Burrows, G.D., Norman, T.R., Judd, F.K., 1994. Definition and differential diagnosis of treatment-resistant depression. Int. Clin. Psychopharmacol. 9 (2), 5-10.
4. Ekdawi, M.Y., 1975. Viloxazine (Vivalan) comparison with imipramine. J. Int. Med. 3 (3), 75-79.
5. Enemark, B., 1993. The importance of ECG monitoring in antidepressant treatment. Nord. J. Psychiatry 47 (30), 57-65.
6. Ferrari, G., Berardi, D., Berlinzani, L., Bellini, M., Cervino, G., Innamorati, A., 1987. A double-blind comparative trial with viloxazine and amitriptyline in inpatients with major non-psychotic depressive disorders. Curr. Ther. Res. 42 (6), 1088-1095.
7. Guelfi, J.D., Dreyfus, J.F., 1983. Une étude comparatice controlée en simple insu de la viloxazine et de la clomipramine par vaè injectable. Actualités Psychiatriques 9, 148-152.
8. Guy, W., 1976. Early Clinical Drug Evaluation (ECDEU) Assessment Manual for Psychopharmacology. National Institute of Mental Health. Publication No. 76-338, Rockville, Maryland.
9. Jungkunz, G., Kuss, H.J., Dieterle, D., 1984. Vergleich der Infusionsbehandlung mit der peroralen Applikation von Clomipramin bei endogen depressiven Patienten-Eine Doppelblindstudie mit Plasmaspiegelbestimmungen. In: Kielholz, P., Adams, C. (Eds.), Tropfinfusionen in der Depressionsbehandlung. Thieme, Stuttgart.
10. Kragh-Sørensen, P., Fredericson Overø, K., Lindegaard Pedersen, O., Jensen, K., Parnas, W., 1981. The kinetics of citalopram: single and multiple dose studies in man. Acta Pharmacol. Toxicol. 48, 53-60.
11. Laux, G., König, W., 1992. Infusionstherapie bei Depressionen. Ein Leitfaden für Klinik und Praxis. Hippokrates, 3. Auflage.
12. Laux, G., König, W., Lesch, K.P., Stein, A., 1989. Intravenöse versus orale Behandlung endogen depressiver Patienten mit Doxepin-Eine Doppelblindstudie mit Plasmaspiegelbestimmungen. Wien. Med. Wschr. 139, 525-529.
13. Lingjaerde, O., Ahlfors, U.G., Bech, P., Dencker, S.J., Elgen, K., 1987. The UKU side effect rating scale. Acta Psychiatr. Scand. 76 (334), 85-100.
14. Lyby, K., Eisborg, L., Høpfner Petersen, H.E., Skovlund, E., 1988. Long-Term Safety of Citalopram. XVI th C.I.N.P. Congress, Munich.
15. Milne, R.J., Goa, K.L., 1991. Citalopram, a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. Drugs 41, 450-477.
16. Montgomery, S.A., 1994. Clinically relevant effect sizes in depression. Eur. Neuropsychopharmacol. 4 (3), 283-284.
17. Montgomery, S.A., Pedersen, V., Tanghøj, P., Rasmussen, C., Rioux, P., 1994. The optimal dosing regimen for citalopram-a meta-analysis of nine placebo-controlled studies. Int. Clin. Psychopharmacol. 9(1), 35-40.
18. Montgomery, S.A., Asberg, M., 1979. A new depression scale designed to be sensitive to change. Br. J. Psychiatry 134, 382-389.
19. Moron, P., Parant-Lucena, N., Franc, R., 1981. Etude comparée en double-insu de la clomipramine et de la viloxazine injectables dans les dépressions sévères. Depression et Suicide. Oxford: Pergamon.
20. Nil, R., 1993. Post marketing surveillance Studien mit dem neuen Antidepressivum Citalopram. In: P. Baumann (Ed.), Biologische Psychiatrie der Gegenwart, Springer-Verlag, Wien, New York, pp. 339-342.
21. Pinder, R.M., Brogen, R.N., Speight, T.M., Avery, G.S., 1977. Viloxazine: A review of its pharmacological properties and therapeutic efficacy in depressive illness. Drugs 13, 401-421.
22. Preskorn, S.H., 1993. Sudden death and tricyclic antidepressants (TCA): a rare adverse event linked to high TCA plasma levels. Nordic. J. Psychiatry 47 (30), 57-65.
23. Schöny, W., 1992. Die Wirksamkeit und Verträglichkeit von Citalopram im Vergleich von parenteraler und oraler Verabreichung. Neuropsychiatrie 6 (1-2), 65-71.
24. Thompson, C., Isaacs, G., 1991. Is viloxazine an antidepressant? A placebo-controlled double-blind study in major depressive disorder presented in a general hospital. Human Psychopharmacology 6, 31-38.